Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Is It Closing Time At The Biotech Bar?
CVS Says New Cholesterol Drug Types Could Be Costly
Strong Dollar Hurts Profit Forecasts In Long Term (Seeking Alpha)
Related SNY
CVS Says New Cholesterol Drug Types Could Be Costly
8 Healthcare Names Cowen & Co Are Talking About
MannKind Valuation Scenarios (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters